$BLBD

Director Phil Horlock Sells 15,381 Shares of Blue Bird Corp

Phil Horlock, a Director at Blue Bird Corp (BLBD), sold 15,381 shares of the company on December 12, 2025, reducing his total holdings to 225,385 shares. Over the past year, Horlock has sold 167,089 shares with no purchases, while the company has seen 3 insider buys and 15 insider sells. Blue Bird Corp is currently trading at $50.42, which is considered modestly overvalued compared to its GF Value of $40.56.

Original reporting
GuruFocus · NULL
Published Dec 16, 2025, 10:18 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Dec 16, 2025, 11:30 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Director Phil Horlock Sells 15,381 Shares of Blue Bird Corp — source image
Decision brief

The 30-second read

$BLBDBearishMed
01

Why it matters

The insider sale coincides with the stock trading at a modest premium over its GF Value, indicating possible profit-taking rather than fundamental concerns.

02

Market read

While insider activity can influence short-term trading, the overall impact is limited given the stock's overvaluation and lack of recent insider purchases.

03

What to watch

Recent company performance, upcoming earnings reports, and broader economic conditions could offset insider sale signals.

Timing: short to medium term

Background

Phil Horlock, a director at Blue Bird Corp, sold 15,381 shares on December 12, 2025, reducing his holdings to 225,385 shares. Over the past year, he has sold 167,089 shares with no purchases, amidst a period where the company's stock has been trading above its intrinsic value.

Company-level read

Ticker impact

$BLBDBearishMedium confidence
Context

The insider selling activity at Blue Bird Corp (BLBD) indicates potential concerns about the company's near-term prospects.

Expected impact

Potential short-term price decline of approximately 2-4% due to insider sale, but long-term impact uncertain.

Evidence & confidence

Insider sales can signal lack of confidence, but the absence of recent insider purchases and the stock's overvaluation suggest caution rather than immediate decline.

Market effects

The manufacturing and earnings sectors may experience slight negative sentiment due to insider activity at Blue Bird Corp.

Limited regional impact given the company's US focus.

Low; company-specific news with minimal global market influence.

Counterpoint

The insider sale may be motivated by personal financial planning rather than company outlook; the stock's overvaluation suggests a potential correction, but not necessarily a decline driven solely by insider activity.

Key entities

  • Phil Horlock

    Director at Blue Bird Corp who recently sold shares.

  • Blue Bird Corp

    Manufacturer in the transportation industry, currently trading at $50.42.

Related articles

$BLBDMedAI 8/10

Blue Bird’s (NASDAQ:BLBD) Q2 CY2026: Beats On Revenue

Blue Bird (NASDAQ:BLBD) reported Q2 CY2026 revenue of $517.2 million, up 29.9% year over year and 3.8% above Wall Street estimates, according to the company. Non-GAAP adjusted EPS was $1.28, up from $1.19 but 1.6% below consensus. The company guided full-year revenue to about $1.75 billion and expected EPS growth to $5.28.

$BLBDHigh

Blue Bird Corp (BLBD): Results of Operations and Financial Condition

Blue Bird Corp (BLBD) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 a2026q3resultsreleaseex991.htm EX-99.1 Document BLUE BIRD REPORTS FISCAL 2026 THIRD QUARTER RESULTS Net Sales of $517M and GAAP Net Income of $185M Adj. EBITDA of $71M with 14% Margin and 3,525 Buses Sold FY2026 Adj. EBITDA Guidance Raised MACON, Ga. (August 5, 2026) –

$BLBDMed

Blue Bird (BLBD) Stock Trades Up, Here Is Why

Blue Bird (BLBD) shares rose about 4% to $81.53 after Barclays raised its price target to $85 from $75 and kept an Overweight rating. Barclays cited updated machinery and construction forecasts, production trends, new awards, pricing, and acquisitions, plus Blue Bird’s cash generation and balance sheet. The stock hit an all-time high; analysts noted revenue declines and capacity limits.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

$SUNEMedAI 8/10

Pentagon to invest $400m in Australian rare earth mine

Sunrise Energy Metals said the US Pentagon will provide a conditional $400 million loan commitment to develop Syerston, a proposed scandium mine in Fifield, NSW. The project targets Western supply of scandium used in defence and other sectors amid China’s export restrictions. Sunrise also said it has a deal with Lockheed Martin for 25% of output for five years.